| Literature DB >> 25922669 |
Gretel Van Esch1, Johan Van Broeck2, Michel Delmée2, Boudewijn Catry3.
Abstract
BACKGROUND: Following an exceptionally high Clostridium difficile infections (CDI) incidence (Spring 2011) in a psychogeriatric long-term care facility, a bidirectional study (2009-2012) was initiated to identify determinants (retrospectively) and to assess intervention measures taken (prospectively).Entities:
Keywords: Clostridium difficile; Intervention; LTCF; Nutritional status
Year: 2015 PMID: 25922669 PMCID: PMC4411800 DOI: 10.1186/s13690-015-0067-y
Source DB: PubMed Journal: Arch Public Health ISSN: 0778-7367
Overview of patient characteristics abstracted from the medical records of cases and controls in a long-term psychogeriatric health care institute, Belgium 2011
| General patient characteristics: | |
|
| (years) at admission |
|
| (kg/m2) at admission |
|
| at admission and at discharge according to Drubbel |
|
| (mg/dL or g/L) at admission based on prealbumine: (<20 mg/dl = malnutrition, >20 mg/dL = normal). If not available, based on total protein: <5,0 g/L malnutrition, >5,0 g/L normal) [ |
|
| (x/30) during stay to assess the cognitive functioning. MMSE below 21/30 is a usual cut-off to define dementia [ |
| CDI specific characteristics: | |
|
| (days), the date at which lab results confirm the clinical diagnosis is taken as the date of infection |
|
| (days) between admission and discharge |
|
| metronidazole or vancomycin |
|
| (days) |
|
| (%) |
| Literature reported CDI risk factors: | |
|
| one month prior to admission, i.e. previous health care exposure (acute hospital, nursing home, LTCF) |
|
| used one month prior to CDI |
|
| used at admission (proton pump inhibitor or histamin-2 blockers or none) |
|
| used at admission |
|
| at admission (yes/no) |
CDI: Clostridium difficile infection; LTCF: long-term care facility.
Figure 1Graphical overview of the incidence of infection (CDI) in a long-term psychogeriatric institution between 2009 and 2012, Belgium.
Comparison of patients’ characteristics of infection (CDI) events and controls
|
|
|
| |||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| Age (years) | 82 | 7,3 | (64–99) | 82 | 7 | (66–97) | 0,77 |
| BMI (kg/m2) | 23 | 5,1 | (15–37) | 23 | 5,5 | (15–40) | 0,88 |
| FI-admission | 0,38 | 0,09 | (0,25-0,55) | 0,38 | 0,07 | (0,22-0,53) | 0,62 |
| total protein (g/L) | 5,8 | 0,9 | (4–8) | 5,4 | 0,8 | (4–8) | 0,03* |
| Prealbumine (mg/dL) | 20,6 | 7 | (8–35) | 16,6 | 7,4 | (5–41) | 0,03* |
| MMSE (x/30) | 22 | 6 | (7–30) | 21 | 7,3 | (0–30) | 0,68 |
§p-value: from independent t-test; *: significant at p<0,05.
For abbreviations: see Table 1.
Figure 2Vancomycin (blue) or metronidazole (green) treatment counts for infections (CDI), separated between relapse and non-relapse cases.
Statistical analysis of the literature reported infection (CDI) risk factors for all patients in the study
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
|
| ||
| Previous health care exposure | 53/61 | 87 | 64/66 | 97 | 0,152 |
| • Acute hospital | 52/53 | 98 | 62/64 | 97 | |
| • Nursing home | 1/53 | 2 | 1/64 | 1,5 | |
| • LTCFa | 0/53 | 0 | 1/64 | 1,5 | |
| Any antibiotic use during 1 month preceding symptom onset | 33/52 | 63 | 58/66 | 88 | 0,001* |
| • Clindamycin | 1/49 | 2 | 2/84 | 2,3 | |
| • Fluoroquinolones | 7/49 | 14 | 13/84 | 15,4 | |
| • Amoxicillin–clavulanic acid | 22/49 | 45 | 36/84 | 43 | |
| • Otherb | 19/49 | 39 | 33/84 | 39 | |
| Antacids use at admission | 39/55 | 71 | 48/57 | 84 | 0,138 |
| • Histamine 2-blocker | 5/39 | 13 | 3/48 | 6 | |
| • Proton-pump inhibitor (PPI) | 34/39 | 87 | 45/48 | 94 | |
| Number of narcotics at admission | 47/53 | 89 | 48/58 | 83 | 0,832 |
| • 1 narcotic | 21/47 | 45 | 17/48 | 35 | |
| • 2 narcotics | 15/47 | 32 | 16/48 | 33 | |
| • 3 narcotics | 7/47 | 15 | 11/48 | 23 | |
| • 4 narcotics | 3/47 | 6 | 3/48 | 6 | |
| • 5 narcotics | 1/47 | 2 | 1/48 | 2 | |
| Diabetes mellitus | 14/57 | 25 | 11/64 | 17 | 0,317 |
aLTCF: long-term care facility.
b’other’ includes cephalosporins, tetracyclines, macrolides and cotrimoxazole (trimethoprim + sulphonamides).
The last column reports the p-value of Chi2-test for nominal data. The values marked with the asterix are significant at the 0,05 level.
Figure 3Graphical overview of the monthly incidence of infection (CDI) in the institution in 2011. Line 1: First awareness moment with communication of increase in incidence. Line 2: Formal intervention start, with stringent hygienic protocol, surveillance and uniform antibiotic guidelines.